Showing 464 results
-
Media Release /- Secukinumab met primary endpoints demonstrating statistically significant improvements versus placebo in signs and symptoms of active psoriatic arthritis (PsA) in two pivotal Phase III studies-…
-
Media Release /- There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating form of MS characterized by gradual, irreversible worsening of…
-
Media Release /Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels(1)Signifor LAR, a next-generation somatostatin analog, provides a new option…
-
Media Release /- Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-…
-
Media Release /Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall…
-
Media Release /Statistically significant and clinically important reductions in proteinuria were achieved for the primary endpoint for patients with C3G(1) Additionally, statistically significant reduction in C3…
-
Media Release /- Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association…
-
Media Release /- Arcapta Neohaler is the only once-daily, 24-hour long-acting beta2-agonist approved for maintenance treatment of airflow obstruction in COPD patients- Arcapta Neohaler showed significant…
-
Media Release /Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS)…
-
Media Release /- Psoriasis patients receiving Cosentyx (secukinumab) reported improvements beyond the skin in mobility, self-care, and usual activities versus patients receiving placebo(1)- Skin lesions are only…
